Overview
ENSC market data
Price History
ENSC price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ENSC. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Ensysce Biosciences, Inc. (ENSC)SEC EDGAR · Jul 15, 2026, 8:15 PM
Ensysce Biosciences Issued $5.3M From National Institutes On Drug Abuse To Support Development Of Multi-Pill Abuse Resistance Overdose-Protection TechnologyBenzinga · Jul 14, 2026, 12:02 PM
Ensysce Biosciences Initiates Final State Of Its PF614-MPAR-102 Clinical Trial To Evaluate Multi-Pill Abuse Resistance Overdose-Protection TechnologyBenzinga · Jun 26, 2026, 12:10 PM
Ensysce Biosciences Has Been Granted European Patent Number EP3934635 Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF (FOR THE TREATMENT OR PREVENTION OF ATTENTION DEFICIT DISORDER (ADHD))"Benzinga · May 20, 2026, 8:05 PM
Ensysce Biosciences Q1 EPS $(0.52) Beats $(0.73) Estimate, Sales $960.999K Miss $1.900M EstimateBenzinga · May 15, 2026, 8:23 PM